ArchiveSee matrix →ES
Prescription drug

Dapagliflozin (SGLT2)

Prescription drug.
Scientific evidence
Very high
Number of findings
1
Sources
Our own summaries · Cited studies

How to take it

There is no established standard dose for this case; it is advisable to consult a professional.

Safety

Prescription drug.

Effect by goal · level of evidence

Heart failure (with or without diabetes)

reduces Very high study (A)

DAPA-HF trial (4,744 patients): dapagliflozin reduced worsening heart failure and cardiovascular death, whether or not patients had diabetes. It extends the use of SGLT2 inhibitors beyond diabetes. Prescription drug.

View the study (study) →

In depth

Drug · Highest evidence: Very high · 1 finding

⚠️ Prescription drug.

Findings

  • Heart failure (with or without diabetes) — reduces (Very high, study). DAPA-HF trial (4,744 patients): dapagliflozin reduced worsening of heart failure and cardiovascular death, whether or not patients had diabetes. It extends the use of SGLT2 inhibitors beyond diabetes. Prescription drug. 31535829

Information, not medical advice. Prescription drugs require a doctor.

Information, not medical advice. Scientific evidence reflects the quality of the studies.

Loading assistant…